Product
Modified FFX
1 clinical trial
1 indication
Indication
InflammationClinical trial
Phase I Study of the First-In-Class Agent CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal CancerStatus: Withdrawn, Estimated PCD: 2024-03-01